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Abstract
Adverse effects of erythropoietin (EPO) on tumor progression and survival were observed in recent phase 3
oncology trials. However, mechanisms remain poorly understood. We tested the effects of exogenous EPO on
murine B16F10 melanoma growth in a subcutaneous tumor transplant model, and for the first time, in a model
of spontaneous tumor formation within autochthonous epithelial tissues using murine mammary tumor virus pro-
moter polyoma virus middle T antigen (MMTV-PyMT) transgenic mice. EPO receptor (EPOR) messenger RNA
(mRNA) was detectable in both B16F10 tumors and mammary tumors from MMTV-PyMT mice but was 0.12 ±
0.02% and 1.3 ± 0.91% of the EPOR mRNA level in murine erythroid HCD-57 cells, respectively. B16F10 tumor
growth rates in mice treated for 3 weeks with 30 μg/kg per week of darbepoetin α, 0.41 inverse days (range, 0.05-
0.69 inverse days; n = 16), were similar to tumor growth rates observed in mice treated with PBS, 0.42 inverse days
(range, 0.10-0.69 inverse days; n = 17). In contrast, darbepoetin α raised hematocrit levels to 0.593 (maximum,
0.729) compared with 0.448 (maximum, 0.532) in PBS-treated mice (P = .0004). In MMTV-PyMT mice, the weights
of tumor-bearingmammary glands inmice treated for 6 weeks with 30 μg/kg per week of darbepoetin α, 3.37 g (range,
1.94-5.81 g; n = 27), did not significantly differ from the weights in PBS-treated mice, 3.76 g (range, 2.30-6.33 g;
n = 26). In contrast, darbepoetin α raised hematocrit levels to 0.441 (maximum, 0.606) compared with 0.405 (maxi-
mum, 0.492) in PBS-treated mice (P= .05). Thus, effects of exogenous EPO on tumor growth were not recapitulated
in these murine tumor models.
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Introduction
Recombinant erythropoietin (EPO) revolutionized the treatment of
chemotherapy-induced anemia by reducing red cell transfusions, but
recent clinical trials indicate that EPO may worsen cancer survival
[1–8]. Whereas venous thromboembolism associated with EPO ther-
apy is a well-recognized risk, the extent to which EPO may stimulate
tumor progression through effects on tumor cells, tumor blood vessels,
and alternate mechanisms remains unclear. The notion that EPO exerts
off-target effects is supported by the observed activity of this growth
factor in a variety of nonhematopoietic tissues including the endo-
thelium, uterus, heart, brain, retina, muscle, and kidney [9]. Binding
sites for EPO in malignant lung cancer cells were discovered more than
15 years ago [10], and EPO receptor (EPOR) mRNA and protein expres-
sion has since been detected in diverse cancer types [11]. Whereas the
potential for EPO to promote tumor growth was raised almost 50 years
ago [12], concern was elevated by the adverse effects of EPO on tumor
progression and survival observed in the aforementioned oncology trials.
While definitive determination of the risk of EPO-induced tumor
progression must come from clinical investigations, studies in cell
lines and animal models may yield insights into mechanisms of
EPO-induced off-target effects. In vitro studies using cancer cell lines,
although disparate, suggest that EPO/EPOR signal transduction can
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stimulate the proliferation, survival, and/or migration of at least certain
malignant cell lines [11]. Animal models allow the opportunity to in-
vestigate the effects of EPO on tumors in a physiologic context. In at
least eight independent studies of both syngeneic and xenogeneic sub-
cutaneous tumor implantation, exogenous EPO administration at
doses that significantly increased hematocrit levels did not alter tumor
growth, angiogenesis, chemosensitivity, or radiosensitivity [11,13]. Fur-
thermore, in at least 10 studies, exogenous EPO actually enhanced the
effects of chemotherapy, radiotherapy, or photodynamic therapy on
tumor ablation, and in two studies, EPO alone seemed to stimulate
tumor regression [13]. In contrast, EPO increased tumor growth in a
syngeneic tumor implant model and in a methylcholanthrene-induced
fibrosarcoma model, effects that were attributed to increased tumor
microvessel density [14]. Similarly, coadministration of EPO along with
syngeneic breast tumor implants in a rat skin-fold window chamber
model increased neovascularization and tumor growth [15]. In addi-
tion, EPO was reported to enhance the growth of human tumor xeno-
grafts after mock surgical trauma [16]. Finally, several studies have
investigated the effects of local EPO blockade on tumor growth. Local
injections of soluble EPOR, anti-EPO antibodies, and antagonistic
EPOmimetic peptides resulted in tumor cell destruction and reduction
of vascularity in human tumor xenografts [17,18]. Similarly, soluble
EPOR, anti-EPO antibodies, and a nonfunctional mutant ligand
(EPO103A) reduced angiogenesis and delayed growth of syngeneic tu-
mors in the aforementioned rat skin-fold window chamber model [15].
All of the above studies involved the formation of subcutaneous
tumors by transplanting cancer cell lines or chemical induced carci-
nogenesis. For the first time, we sought to test the effects of EPO on
tumor growth using tumors formed spontaneously within endoge-
nous epithelial tissues, a process that more closely reflects the com-
plexity of human tumorigenesis and tumor progression including
interactions with endogenous tissue–specific stroma. For this initial
study, we focused on measurements of tumor growth using the murine
mammary tumor virus promoter polyoma virus middle T antigen
(MMTV-PyMT) transgenic model on the FVB strain. These mice
reproducibly develop pregnancy-independent multifocal mammary
tumors with a mean latency of only 53 days in 100% of females
[19,20]. PyMT is a potent oncogene that targets several signal transduc-
tion pathways that are altered in human breast cancer [21]. Tumors in
MMTV-PyMTmice progress through stages of hyperplasia, adenoma/
mammary intraepithelial neoplasia, early and late carcinoma, and me-
tastasis that are comparable to human breast cancer [22]. As in the hu-
man disease, loss of estrogen receptor, progesterone receptor, and
integrin-β and sustained expression of erbB2 and cyclin D1 are all as-
sociated with poor prognosis [22]. In an effort to establish a preclinical
animal model for studies of EPO-induced tumor progression, we com-
pared the effects of EPO on tumor growth in a syngeneic tumor trans-
plantation model versus a transgenic model of spontaneous cancer
within endogenous mammary epithelium. We found that EPO did
not accelerate tumor formation or growth in these models. The limita-




All procedures were approved by the Institutional Animal Care
and Use Committee of the University of Washington. C57BL/6
and FVB mice were purchased from Taconic (Hudson, NY) and were
maintained under specific pathogen-free conditions at the University
of Washington. MMTV-PyMT mice on the FVB background were
generously provided by Dr Sandra Gendler and were genotyped as
described [23].
B16F10 Tumor Formation in Syngeneic C57BL/6 Mice
Murine B16F10 melanoma cells were obtained from the American
Type Culture Collection (Manassas, VA) and were cultured in Dul-
becco’s modified Eagle medium, 10% heat-inactivated fetal bovine
serum, 100 U/ml penicillin G, 0.10 mg/ml streptomycin sulfate,
and 0.25 μg/ml amphotericin B. Cells were washed three times in
PBS and were resuspended in PBS at a concentration of 1 million
cells per 300 μl. On day 0, C57BL/6 mice (aged 9-10 weeks) were
anesthetized using an isoflurane/oxygen vaporizer, their flanks were
shaved, and they received a subcutaneous injection of 1 million cells.
Mice were stratified by sex and were randomly assigned to receive
subcutaneous injections of darbepoetin α (30 μg/kg per week; Amgen,
Thousand Oaks, CA) or an equal volume of PBS starting on the day of
tumor injection. Equal numbers of mice were assigned to darbepoetin
α versus PBS for each cell preparation. To ensure that sex did not con-
found results, males and females were equally distributed to EPO and
PBS groups. Tumor measurements were obtained in anesthetized mice
in the cranial/caudal (length), superior/inferior (height), and medial/
lateral (width) directions using Vernier calipers. In experiment 1 (n =
8), darbepoetin α or PBS was injected on days 0 and 7, tumors were
measured on days 10 and 14, and hematocrit levels were not deter-
mined. In experiments 2 to 4, darbepoetin α or PBS was injected on
days 0, 7, and 14; tumors were measured on days 7, 14, 17, and 20; and
hematocrit levels were determined on day 20. Tumor-bearing mice
were monitored daily (no morbidity was observed) and were humanely
killed on the last day of tumor measurement or sooner on excessive tu-
mor burden in accordance with local animal ethics regulations. Tumor
volume was calculated using the following formula: 0.5 × length ×
width × height. Tumor growth was determined using the following
formula: 1 / doubling time, where doubling time = (T − T 0) × log2/
(logV − logV 0), and T − T 0 indicates the difference in time between
tumor measurements and V and V 0 indicate the tumor volume at the
two times of measurement.
Analysis of Tumor Growth in MMTV-PyMT Mice
Heterozygous MMTV-PyMT males were bred to wild-type FVB
females, and heterozygous female offspring without palpable mam-
mary tumors were accrued to the study when they reached 48 to
51 days old. On day 0, mice were randomly assigned to subcutaneous
injections of darbepoetin α (30 μg/kg per week) or PBS continuing
weekly. Three mice each received a total of five injections of darbepoetin
α or PBS and were humanely killed on day 31, whereas all remaining
mice (n = 48) received a total of six injections and were humanely killed
on day 37. Mice were inspected weekly by an investigator blinded to
treatment assignment to determine the time to first visible tumor.
Tumor-bearing mice were monitored daily (no morbidity was observed)
and were humanely killed at the study end point or sooner on excessive
tumor burden. Hematocrit levels were determined at the study end
point using heparinized microhematocrit capillary tubes (Fisher Scien-
tific, Pittsburgh, PA) and a microhematocrit centrifuge (Damon/IEC,
now ThermoScientific, Waltham, MA). All mammary glands (includ-
ing thoracic and inguinal) were collected on sacrifice and weighed, and
their volume was determined by PBS displacement. Mammary gland
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weights were not obtained for one mouse in the PBS group that was
removed from the study early to provide tissue for assay development.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Total RNA was extracted from B16F10 tumors and MMTV-
PyMT tumor-bearing mammary glands using the miRNeasy Mini
Kit (Qiagen, Valencia, CA) with on-columnDnaseI digestion to remove
genomic DNA. First-strand complementary DNA was synthesized
using random hexamers and SuperScript III reverse transcriptase
(Invitrogen, Carlsbad, CA). Triplicate quantitative polymerase chain re-
actions (PCRs) were performed for each sample using TaqMan assays for
EPOR (assay identification number Mm00833882_m1), the reference
gene PGK1 (Mm00435617_m1), and standard thermal cycling con-
ditions (Applied Biosystems, Foster City, CA). The coefficient of varia-
tion for triplicate PCRs was less than 1.6% for all samples. Relative
quantification was determined using the comparative cycle threshold
(C t) method, 2
−ΔC t where ΔC t = mean C t for target gene − mean C t
for reference gene.
Results and Discussion
EPO Does Not Increase the Growth of B16F10
Subcutaneous Implants
We first tested the effects of exogenous EPO administration in
a syngeneic subcutaneous tumor implant model. We used B16F10
murine melanoma cells because they are known to develop as tumors
when injected subcutaneously in syngeneic C57BL/6 hosts, and no
previous studies have examined the effects of EPO on B16F10 mela-
noma growth. Tumor take rates in mice treated with darbepoetin α
(14/18 on day 10 and 16/18 on day 17) were comparable to those in
the PBS group (14/19 on day 10 and 17/19 on day 17). Likewise, the
tumors in mice treated with darbepoetin α neither were larger (Figure 1)
nor grew faster than tumors in mice treated with PBS (Figure 2). The
biologic activity of darbepoetin α in this setting was confirmed by
significantly increased hematocrit levels to a mean of 0.593 (maxi-
mum, 0.729) compared with 0.448 (maximum, 0.532) in PBS-treated
mice (P = .0004).
EPOR mRNA was detectable in B16F10 tumors but was less than
0.12 ± 0.02 of the EPOR mRNA level in control murine EPO-
dependent HCD-57 cells [24] (n = 15). The lack of effects of
EPO on tumor growth in this model may be related to this low level
of EPOR in the B16F10 tumor cells. In addition, the rapid growth
rate of B16F10 cells in this syngeneic tumor transplant system pro-
vided only a limited window for EPO dosing. Although we did not
assess the possibility that EPO may have subtly increased tumor mi-
crovessel density, such an effect is unlikely because there was no effect
of EPO on tumor growth.
EPO Does Not Increase the Growth of Mammary Tumors in
MMTV-PyMT Mice
No previous studies have examined the effects of EPO on tumors
formed spontaneously within endogenous epithelial tissues. We exam-
ined whether exogenous EPO administration influences mammary
tumor growth using MMTV-PyMTmice. This model provided the
opportunity to administer EPO before the onset of tumors and during
Figure 1. EPO does not increase the volume of subcutaneous
B16F10 melanoma tumors. Mice were inoculated on day 0 with
B16F10 cells, and EPO or PBS was administered at the time of
tumor cell implantation continuing weekly for a total of two injec-
tions (Exp. 1) or three injections (Exp. 2-4). The tumor volumes at
days 10 and 14 (Exp. 1) or at days 10, 14, 17, and 20 (Exp. 2-4) are
plotted relative to the maximal tumor volume observed in each
experiment. *Mice removed from the study before the end point
owing to excessive tumor growth. †Mouse that died.
Figure 2. EPO does not increase the growth rate of subcutaneous
B16F10 melanoma tumors. Mice were treated as described in Fig-
ure 1. The distribution of tumor growth rates in the mice treated
with EPO or PBS is summarized for the mice in all four experi-
ments. The mean growth rates are indexed by the horizontal bars.
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tumor growth. Mice without palpable tumors at days 48 to 51 of age
were randomly assigned to darbepoetin α or PBS. Visible tumors were
detected in the mammary glands of darbepoetin α–treated mice 3.8 ±
1.1 weeks later (n = 27) and in PBS-treated mice 3.6 ± 1.1 weeks later
(n = 27; Figure 3). Thus, darbepoetin α did not accelerate the rate of
initial tumor formation. Similarly, the weights of tumor-bearing mam-
mary glands at the study end point in darbepoetin α–treated mice,
3.37 g (range, 1.94-5.81 g), did not significantly differ from the weights
in PBS-treated mice, 3.76 g (range, 2.30-6.33 g; Figure 4). Similar re-
sults were obtained when tumor volumes were measured by liquid dis-
placement (data not shown). In contrast, darbepoetin α significantly
raised hematocrit levels to 0.441 (maximum, 0.606) compared with
0.405 (maximum, 0.492) in PBS-treated mice (P = .05). Of note, the
hematocrit value for one mouse in the darbepoetin α group could not
be determined due to clotting in the microhematocrit tube. When three
additional mice with hematocrit determinations less than 0.30 were ex-
cluded from the darbepoetin α group, the significance of the difference
in hematocrit levels between the darbepoetin α and PBS groups was
increased (P = .0006).
The absence of an effect of EPO on tumor growth may be related
to the low EPOR mRNA levels in MMTV-PyMT tumors. Although
detectable, EPOR mRNA levels in tumor-bearing mammary glands
fromMMTV-PyMTmice (n = 7) were only 1.13 ± 0.91% of the EPOR
mRNA level in control murine erythroid HCD-57 cells. Another
limitation of the MMTV-PyMT-FVB model is the short window avail-
able for EPO administration during the tumor growth phase. Less than
6 weeks were available before animals had to be humanely killed owing
to the rapid growth of tumors. Of note, the expression of the MMTV-
PyMT transgene on the C57BL/6 background has been shown to result
in significantly delayed tumor latency of 92 days compared with 53 days
in the FVB strain [20].
In several investigations, EPO’s tumor growth–promoting activity
was attributed to proangiogenic effects [14,15,17,18]. Because EPO
did not promote tumor growth in the MMTV-PyMT-FVB mice, we
did not undertake secondary studies to uncover possible mechanisms
of action of EPO such as quantification of tumor microvessel density.
Such studies are better suited to tumor models that may be more
sensitive to the effects of exogenous factors on tumor angiogenesis.
For example, mammary tumors from (MMTV-PyMT-FVB × I/LnJ)
F1 hybrids exhibit a 20% reduction in tumor growth and a five-fold
reduction in interior tumor microvessel density compared with tumors
from the FVB strain [25]. Future studies using theMMTV-PyMTmice
of alternate strains and other transgenic models with relatively slower
tumor growth rates, higher tumor EPOR expression levels, or sensitivity
to the effects of EPO on tumor angiogenesis may be needed to detect
effects of EPO on tumor growth.
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